من نحن

The Osteosarcoma Institute (OSI) invites applications for grant funding to advance clinical trials, correlative science, and preclinical or translational research projects focused on osteosarcoma. Guided by a Strategic Advisory Board of leading physicians and researchers, OSI employs a multifaceted grant strategy to accelerate progress in osteosarcoma research and improve outcomes for patients with relapsed or metastatic disease. Funding is available across four program areas: Clinical Trials (Phase I/II or Phase II trials in relapsed or refractory osteosarcoma, up to USD 800,000 over 2–3 years), Correlative Science (studies generating biological data from clinical trials, USD 200,000–500,000 over 2 years), Preclinical/Translational Research (projects identifying biological dependencies for therapeutic targeting, up to USD 500,000 over 2 years), and High‑Risk/High‑Impact initiatives (USD 25,000–125,000 over 1 year). All grants include indirect costs as specified. Through these programs, OSI seeks to provide both immediate and long‑term hope for patients by supporting innovative, scientifically rigorous projects worldwide.

معايير القبول

Applicants must be appointed faculty (or equivalent) at an academic institution and hold an MD, PhD, MD/PhD, or equivalent degree, with a demonstrated track record of publication and funding productivity. Grants are awarded only to nonprofit or charitable organizations, which may be based in any country, provided they can document their charitable status. Each applicant may submit only one letter of intent per cycle, and all applications must comply with OSI’s submission instructions and deadlines.

Post Date: August 12, 2026